Dr. Weng is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
12200 Annapolis Rd
Glenn Dale, MD 20769Phone+1 410-897-6200Fax+1 410-266-7636- Is this information wrong?
Summary
- Dr. David Weng is an oncologist in the Baltimore-Washington DC area with Maryland Oncology Hematology. He received his undergraduate degree from Harvard College, medical degree and Ph.D from Johns Hopkins University School of Medicine. He did his medical oncology fellowship at the NIH. He is board certified and treats all solid tumor and hematologic malignancies. He is particularly experienced in the care of patients with breast cancer, GI cancer, lung cancer, gynecologic cancer, multiple myeloma, and lymphomas. He also has significant expertise for symptom management care. He has an extensive background in cancer translational and clinical research. His career activities have included substantial experiences in government, academic, biotechnology and community practice settings.
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1995 - 1998
- Johns Hopkins UniversityResidency, Internal Medicine, 1992 - 1995
- Johns Hopkins University School of MedicineClass of 1992
- Harvard UniversityAB, Biochemistry, Magna Cum Laude, 1980 - 1984
Certifications & Licensure
- CA State Medical License 2013 - 2026
- OH State Medical License 1998 - 2025
- MD State Medical License 1995 - 2025
- American Board of Internal Medicine Medical Oncology
- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Clinical Trials
- A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer Start of enrollment: 2008 Apr 01
Publications & Presentations
PubMed
- 71 citationsAngiozyme: a novel angiogenesis inhibitor.David E. Weng, Nassim Usman> ;Current Oncology Reports. 2001 Mar 1
- 11 citationsReCAP: Insights Into the Potential Preventability of Oncology ReadmissionsElizabeth Hahn, Madelaine Binner, David Weng> ;Journal of Oncology Practice. 2016 Jan 19
- 81 citationsA Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma.Ravi K. Amaravadi, Russell J. Schilder, Lainie P. Martin, Myron J. Levin, Martin A. Graham, David E. Weng, Alex A. Adjei> ;Molecular Cancer Therapeutics. 2015 Sep 2
- Join now to see all
Press Mentions
- David Weng: We Created Maryland Oncology Hematology to Improve Oncology Care in This Community | COMMENTARYMarch 7th, 2021
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: